COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission

Protocol No
ECOG-EA4151
Principal Investigator
Timothy Fenske
Phase
III
Summary
To determine whether an autotransplant improves survival in MCL patients who have achieved an excellent (MRD-negative) first complete remission (CR).
Description
Rituximab with or without SCT in Treating Pt with MRD-Neg MCL in First Complete Remission
Participating Institutions
Froedtert Hospital
Moorland Reserve Health Center
Status
OPEN TO ACCRUAL